|
|
|
|
|
28.02.26 - 08:00
|
Krise im Schweizerland: Brack entlässt 45 Leute (Inside Paradeplatz)
|
|
|
Übernahme der Schönheits-Onlineshops PerfectHair.ch führt zu Massenentlassung. „Höchst unwahrscheinliches Maximum“, sagt Brack.
Die Schweizer Wirtschaft erlebt ihren Dauer-Abbau. Diese Woche meldete die Pharmafirma Galenica das Aus ihrer Produktion in Interlaken. 170 Jobs fallen ins Wasser. Idorsia, ein anderer bekannter Name der Gesundheitsindustrie, strich am Donnerstag gar 200 Stellen. Jetzt kommen in Zürich-Nord […]...
|
|
|
|
|
28.02.26 - 04:24
|
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC (PR Newswire)
|
|
|
NEW YORK and NEW ORLEANS, Feb. 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a......
|
|
|
28.02.26 - 00:06
|
The Baldwin Group Announces Future Leadership Transition in its Underwriting, Capacity, and Technology Solutions Segment (Business Wire)
|
|
|
Amy Carlisle to be named CEO; Jim Roche to become Executive ChairmanTAMPA, Fla.--(BUSINESS WIRE)--The Baldwin Group (“Baldwin” or the “Company”) (NASDAQ: BWIN), a leading independent insurance brokerage and advisory firm delivering tailored insurance solutions to a wide range of personal and commercial clients, today announced a long-planned leadership transition within its Underwriting, Capacity, & Technology Solutions (“UCTS”) operating group, effective January 1, 2027. Amy Carlisle will become Chief Executive Officer of UCTS, succeeding Jim Roche, who will assume the role of Executive Chairman, UCTS for a period of three years. The transition reflects a deliberate, multi-year succession plan designed to ensure continuity and support the long-term strength and performance of the UCTS business.
As CEO, UCTS, Ms. Carlisle will oversee the segment's MGA and wholesale businesses, capacity operations, and finance and accounting functions. She will report to Chief Executive Officer, Trevor Baldwi...
|
|
|
|
|
|
|
27.02.26 - 22:33
|
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing (GlobeNewswire EN)
|
|
|
RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continued listing of the Company's American Depositary Shares (“ADSs”) is no longer warranted. The Company intends to request a hearing (the “Hearing”) to appeal the delisting process before a Nasdaq Hearings Panel (the “Panel”). A Hearing request will stay the suspension of the ADSs and delisting pending the Panel's decision....
|
|
|
|
|
27.02.26 - 22:21
|
Prothena Announces up to $100 Million Share Repurchase Plan (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--$PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized a Share Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding ordinary shares, par value $0.01 per share.
Prothena had cash, cash equivalents and restricted cash of $308.4 million and no debt as of December 31, 2025. Excluding any potential purchases under this Share Repurchase Plan, Prothena expects to end the year with approximately $255 million in cash, cash equivalents, and restricted cash. This financial guidance does not include the potential to earn up to $105 million of aggregate clinical milestone payments from strategic partners in 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerativ...
|
|
|
|
|
|
|
27.02.26 - 21:45
|
European health agency recommends approving Moderna′s combined flu, COVID vaccine (The Hill)
|
|
|
The European Medicines Agency (EMA) announced Friday it has recommended Moderna's combined mRNA COVID-19 and flu vaccine be granted market authorization in the European Union, marking the first time the combined respiratory viral vaccine will be approved. "EMA has recommended granting a marketing authorisation in the European Union (EU) for mCombriax, a messenger RNA vaccine......
|
|
|
27.02.26 - 21:45
|
Novo Nordisk Aktie: Eine Vergleichsstudie mit Sprengkraft (Aktiencheck)
|
|
|
Kulmbach (www.aktiencheck.de) - Novo Nordisk-Aktienanalyse von "Der Aktionär":
Alfred Maydorn vom Anlegermagazin "Der Aktionär" nimmt im Interview mit "Der Aktionär TV" die Aktie von Novo Nordisk A/S (ISIN: DK0062498333, WKN: A3EU6F, Ticker-Symbol: NOV, NASDAQ Kopenhagen-Symbol: NOVO B) unter die Lupe. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
27.02.26 - 19:54
|
Trump lobt Novartis-Chef für Schaffung von Arbeitsplätzen in USA (Cash)
|
|
|
- US-Präsident Donald Trump lobt den Konzernchef von Novartis für dessen Reaktion auf die US-Zölle. «Die Zölle haben Novartis und dessen grossartiger CEO Vasant (Vas) Narasimhan, M.D., dazu bewegt, 7+ Produktions- und Forschungsanlagen zu errichten und so Tausende von Arbeitsplätzen zu schaffen», schrieb Trump am Freitagabend auf seiner Plattform Truth Social....
|
|
|
27.02.26 - 19:48
|
The Future of Handheld Retinal Imaging—Live at Vision Expo Booth 2038 (Cision)
|
|
|
At Vision Expo 2026 in Orlando, Optomed will showcase the Optomed Lumo, a handheld, non-mydriatic fundus camera designed to support efficient retinal image capture and documentation across clinical care settings. For added flexibility, the device is available with an optional desktop base.
The Optomed Lumo combines a 12 MP high-sensitivity sensor with Smart Autofocus™ technology and customizable workflows to support the acquisition of high-quality retinal images without dilation.
Key Features
· User-Focused Design: 5” touchscreen with guided user interface to support efficient image...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
